Clinical and Therapeutic Considerations for Older Adults with Head and Neck Cancer

References

• Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941–1953. doi:10.1002/ijc.31937
   PubMed Web of Science ®Google Scholar
• Sikora AG, Toniolo P, DeLacure MD. The changing demographics of head and neck squamous cell carcinoma in the United States. Laryngoscope. 2004;114(11):1915–1923. doi:10.1097/01.mlg.0000147920.66486.bc
   PubMed Web of Science ®Google Scholar
• Hankey BF, Ries LA, Edwards BK. Surveillence, Epidemiology, and End Results Program. N.C. Institute; 2017.
   Google Scholar
• Howlader N. SEER Cancer Statistics Review, 1975–2016. Bethesda, MD: National Cancer Institute; 2019.
   Google Scholar
• Gillison ML, Broutian T, Pickard RKL, et al. Prevalence of oral HPV infection in the United States, 2009–2010. JAMA. 2012;307(7):693–703. doi:10.1001/jama.2012.101
   PubMed Web of Science ®Google Scholar
• Zumsteg ZS, Cook-Wiens G, Yoshida E, et al. Incidence of oropharyngeal cancer among elderly patients in the United States. JAMA Oncol. 2016;2(12):1617–1623. doi:10.1001/jamaoncol.2016.1804
   PubMed Web of Science ®Google Scholar
• Windon MJ, D’Souza G, Rettig EM, et al. Increasing prevalence of human papillomavirus-positive oropharyngeal cancers among older adults. Cancer. 2018;124(14):2993–2999. doi:10.1002/cncr.31385
   PubMed Web of Science ®Google Scholar
• Rettig EM, Fakhry C, Khararjian A, et al. Age profile of patients with oropharyngeal squamous cell carcinoma. JAMA Otolaryngol Head Neck Surg. 2018;144(6):538–539. doi:10.1001/jamaoto.2018.0310
   PubMed Web of Science ®Google Scholar
• Pignon JP, Maître AL, Maillard E, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92(1):4–14. doi:10.1016/j.radonc.2009.04.014
   PubMed Web of Science ®Google Scholar
• VanderWalde NA, Fleming M, Weiss J, et al. Treatment of older patients with head and neck cancer: a review. Oncologist. 2013;18(5):568–578. doi:10.1634/theoncologist.2012-0427
   PubMed Web of Science ®Google Scholar
• Lacas B, Bourhis J, Overgaard J, et al. Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. Lancet Oncol. 2017;18(9):1221–1237. doi:10.1016/S1470-2045(17)30458-8
   PubMed Web of Science ®Google Scholar
• Windon MJ, D’Souza G, Faraji F, et al. Priorities, concerns, and regret among patients with head and neck cancer. Cancer. 2019;125(8):1281–1289. doi:10.1002/cncr.31920
   PubMed Web of Science ®Google Scholar
• Haehl E, Rühle A, David H, et al. Radiotherapy for geriatric head-and-neck cancer patients: what is the value of standard treatment in the elderly? Radiat Oncol. 2020;15(1):31. doi:10.1186/s13014-020-1481-z
   PubMed Web of Science ®Google Scholar
• Tobias JS, Monson K, Gupta N, et al. Chemoradiotherapy for locally advanced head and neck cancer: 10-year follow-up of the UK Head and Neck (UKHAN1) trial. Lancet Oncol. 2010;11(1):66–74. doi:10.1016/S1470-2045(09)70306-7
   PubMed Web of Science ®Google Scholar
• Szturz P, Vermorken JB. Treatment of elderly patients with squamous cell carcinoma of the head and neck. Front Oncol. 2016;6:199. doi:10.3389/fonc.2016.00199
   PubMed Web of Science ®Google Scholar
• Coca‐Pelaz A, Halmos GB, Strojan P, et al. The role of age in treatment-related adverse events in patients with head and neck cancer: a systematic review. Head Neck. 2019;41(7):2410–2429. doi:10.1002/hed.25696
   PubMed Web of Science ®Google Scholar
• Rim CH, Yoon WS, Lee JA, et al. Factors predicting intolerance to definitive conventional radiotherapy in geriatric patients. Strahlenther Onkol. 2018;194(10):894–903. doi:10.1007/s00066-018-1318-y
   PubMed Web of Science ®Google Scholar
• Mady LJ, Baddour K, Hodges JC, et al. The impact of frailty on mortality in non-surgical head and neck cancer treatment: shifting the clinical paradigm. Oral Oncol. 2022;126:105766. doi:10.1016/j.oraloncology.2022.105766
   PubMed Web of Science ®Google Scholar
• Dickstein DR, Egerman M, Monrose E, et al. Treatment tolerability and outcomes in elderly patients with head and neck cancer. Head Neck. 2021;43(3):858–873. doi:10.1002/hed.26548
   PubMed Web of Science ®Google Scholar
• Bese NS, Hendry J, Jeremic B. Effects of prolongation of overall treatment time due to unplanned interruptions during radiotherapy of different tumor sites and practical methods for compensation. Int J Radiat Oncol Biol Phys. 2007;68(3):654–661. doi:10.1016/j.ijrobp.2007.03.010
   PubMed Web of Science ®Google Scholar
• Patel UA, Thakkar KH, Holloway N. Patient compliance to radiation for advanced head and neck cancer at a tertiary care county hospital. Laryngoscope. 2008;118(3):428–432. doi:10.1097/MLG.0b013e31815ae3d2
   PubMed Web of Science ®Google Scholar
• Thomas K, Martin T, Gao A, et al. Interruptions of head and neck radiotherapy across insured and indigent patient populations. J Oncol Pract. 2017;13(4):e319–e328. doi:10.1200/JOP.2016.017863
   PubMed Web of Science ®Google Scholar
• Lazarev S, Gupta V, Ghiassi-Nejad Z, et al. Premature discontinuation of curative radiation therapy: insights from head and neck irradiation. Adv Radiat Oncol. 2018;3(1):62–69. doi:10.1016/j.adro.2017.10.006
   PubMedGoogle Scholar
• Ohri N, Rapkin BD, Guha C, et al. Radiation therapy noncompliance and clinical outcomes in an urban academic cancer center. Int J Radiat Oncol Biol Phys. 2016;95(2):563–570. doi:10.1016/j.ijrobp.2016.01.043
   PubMed Web of Science ®Google Scholar
• Salloum RG, Smith TJ, Jensen GA, et al. Factors associated with adherence to chemotherapy guidelines in patients with non-small cell lung cancer. Lung Cancer. 2012;75(2):255–260. doi:10.1016/j.lungcan.2011.07.005
   PubMed Web of Science ®Google Scholar
• Kroenke CH, Kubzansky LD, Schernhammer ES, et al. Social networks, social support, and survival after breast cancer diagnosis. J Clin Oncol. 2006;24(7):1105–1111. doi:10.1200/JCO.2005.04.2846
   PubMed Web of Science ®Google Scholar
• DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000;160(14):2101–2107. doi:10.1001/archinte.160.14.2101
   PubMed Web of Science ®Google Scholar
• McDermott JD, Eguchi M, Morgan R, et al. Elderly black non-Hispanic patients with head and neck squamous cell cancer have the worst survival outcomes. J Natl Compr Canc Netw. 2020;19(1):57–67. doi:10.6004/jnccn.2020.7607
   PubMed Web of Science ®Google Scholar
• Inverso G, Mahal BA, Aizer AA, et al. Health insurance affects head and neck cancer treatment patterns and outcomes. J Oral Maxillofac Surg. 2016;74(6):1241–1247. doi:10.1016/j.joms.2015.12.023
   PubMed Web of Science ®Google Scholar
• Goyal N, Day A, Epstein J, et al. Head and neck cancer survivorship consensus statement from the American Head and Neck Society. Laryngoscope Investig Otolaryngol. 2022;7(1):70–92. doi:10.1002/lio2.702
   PubMed Web of Science ®Google Scholar
• Mady LJ, Lyu L, Owoc MS, et al. Understanding financial toxicity in head and neck cancer survivors. Oral Oncol. 2019;95:187–193. doi:10.1016/j.oraloncology.2019.06.023
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. doi:10.1016/0021-9681(87)90171-8
   PubMedGoogle Scholar
• Piccirillo JF, Sasaki CT, Wells CK, et al. New clinical severity staging system for cancer of the larynx. Five-year survival rates. Ann Otol Rhinol Laryngol. 1994;103(2):83–92. doi:10.1177/000348949410300201
   PubMed Web of Science ®Google Scholar
• Kaplan MH, Feinstein AR. The importance of classifying initial co-morbidity in evaluating the outcome of diabetes mellitus. J Chronic Dis. 1974;27(7–8):387–404. doi:10.1016/0021-9681(74)90017-4
   PubMedGoogle Scholar
• Reid BC, Alberg AJ, Klassen AC, et al. Comorbidity and survival of elderly head and neck carcinoma patients. Cancer. 2001;92(8):2109–2116. doi:10.1002/1097-0142(20011015)92:8<2109::AID-CNCR1552>3.0.CO;2-M
   PubMed Web of Science ®Google Scholar
• Datema FR, Ferrier MB, van der Schroeff MP, et al. Impact of comorbidity on short-term mortality and overall survival of head and neck cancer patients. Head Neck. 2010;32(6):728–736. doi:10.1002/hed.21245
   PubMed Web of Science ®Google Scholar
• van Deudekom FJ, Schimberg AS, Kallenberg MH, et al. Functional and cognitive impairment, social environment, frailty and adverse health outcomes in older patients with head and neck cancer, a systematic review. Oral Oncol. 2017;64:27–36. doi:10.1016/j.oraloncology.2016.11.013
   PubMed Web of Science ®Google Scholar
• Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on sarcopenia in older people. Age Ageing. 2010;39(4):412–423. doi:10.1093/ageing/afq034
   PubMed Web of Science ®Google Scholar
• Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16–31. doi:10.1093/ageing/afy169
   PubMed Web of Science ®Google Scholar
• Chargi N, Bril SI, Emmelot-Vonk MH, et al. Sarcopenia is a prognostic factor for overall survival in elderly patients with head-and-neck cancer. Eur Arch Otorhinolaryngol. 2019;276(5):1475–1486. doi:10.1007/s00405-019-05361-4
   PubMed Web of Science ®Google Scholar
• Wendrich AW, Swartz JE, Bril SI, et al. Low skeletal muscle mass is a predictive factor for chemotherapy dose-limiting toxicity in patients with locally advanced head and neck cancer. Oral Oncol. 2017;71:26–33. doi:10.1016/j.oraloncology.2017.05.012
   PubMed Web of Science ®Google Scholar
• Bril SI, Al‐Mamgani A, Chargi N, et al. The association of pretreatment low skeletal muscle mass with chemotherapy dose-limiting toxicity in patients with head and neck cancer undergoing primary chemoradiotherapy with high-dose cisplatin. Head Neck. 2022;44(1):189–200. doi:10.1002/hed.26919
   PubMed Web of Science ®Google Scholar
• Haehl E, Alvino L, Rühle A, et al. Sarcopenia as a prognostic marker in elderly head and neck squamous cell carcinoma patients undergoing (chemo-)radiation. Cancers. 2022;14(22):5536. doi:10.3390/cancers14225536
   PubMed Web of Science ®Google Scholar
• National Health. National Center for Health Statistics. United States: In Health; 2019.
   Google Scholar
• Mohamed MR, Ramsdale E, Loh KP, et al. Associations of polypharmacy and inappropriate medications with adverse outcomes in older adults with cancer: a systematic review and meta-analysis. Oncologist. 2020;25(1):e94–e108. doi:10.1634/theoncologist.2019-0406
   PubMed Web of Science ®Google Scholar
• By the American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2019 updated AGS Beers Criteria(R) for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;67(4):674–694. doi:10.1111/jgs.15767
   PubMed Web of Science ®Google Scholar
• Chen LJ, Trares K, Laetsch DC, et al. Systematic review and meta-analysis on the associations of polypharmacy and potentially inappropriate medication with adverse outcomes in older cancer patients. J Gerontol a Biol Sci Med Sci. 2021;76(6):1044–1052. doi:10.1093/gerona/glaa128
   PubMed Web of Science ®Google Scholar
• Caparrotti F, O’Sullivan B, Bratman SV, et al. Exploring the impact of human papillomavirus status, comorbidity, polypharmacy, and treatment intensity on outcome of elderly oropharyngeal cancer patients treated with radiation therapy with or without chemotherapy. Int J Radiat Oncol Biol Phys. 2017;98(4):858–867. doi:10.1016/j.ijrobp.2016.11.044
   PubMed Web of Science ®Google Scholar
• Bellera CA, Rainfray M, Mathoulin-Pélissier S, et al. Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Ann Oncol. 2012;23(8):2166–2172. doi:10.1093/annonc/mdr587
   PubMed Web of Science ®Google Scholar
• Overcash J, Ford N, Kress E, et al. Comprehensive geriatric assessment as a versatile tool to enhance the care of the older person diagnosed with cancer. Geriatrics. 2019;4(2):39. doi:10.3390/geriatrics4020039
   PubMed Web of Science ®Google Scholar
• Overcash JA, Beckstead J, Extermann M, et al. The abbreviated comprehensive geriatric assessment (aCGA): a retrospective analysis. Crit Rev Oncol Hematol. 2005;54(2):129–136. doi:10.1016/j.critrevonc.2004.12.002
   PubMed Web of Science ®Google Scholar
• Saliba D, Elliott M, Rubenstein LZ, et al. The Vulnerable Elders Survey: a tool for identifying vulnerable older people in the community. J Am Geriatr Soc. 2001;49(12):1691–1699. doi:10.1046/j.1532-5415.2001.49281.x
   PubMed Web of Science ®Google Scholar
• Drubbel I, Bleijenberg N, Kranenburg G, et al. Identifying frailty: do the Frailty Index and Groningen Frailty Indicator cover different clinical perspectives? A cross-sectional study. BMC Fam Pract. 2013;14(1):64. doi:10.1186/1471-2296-14-64
   PubMedGoogle Scholar
• Almodovar T, Teixeira E, Barroso A, et al. Elderly patients with advanced NSCLC: the value of geriatric evaluation and the feasibility of CGA alternatives in predicting chemotherapy toxicity. Pulmonology. 2019;25(1):40–50. doi:10.1016/j.pulmoe.2018.07.004
   PubMed Web of Science ®Google Scholar
• Pottel L, Lycke M, Boterberg T, et al. Serial comprehensive geriatric assessment in elderly head and neck cancer patients undergoing curative radiotherapy identifies evolution of multidimensional health problems and is indicative of quality of life. Eur J Cancer Care. 2014;23(3):401–412. doi:10.1111/ecc.12179
   PubMed Web of Science ®Google Scholar
• Pottel L, Lycke M, Boterberg T, et al. G-8 indicates overall and quality-adjusted survival in older head and neck cancer patients treated with curative radiochemotherapy. BMC Cancer. 2015;15(1):875. doi:10.1186/s12885-015-1800-1
   PubMedGoogle Scholar
• Neve M, Jameson MB, Govender S, et al. Impact of geriatric assessment on the management of older adults with head and neck cancer: a pilot study. J Geriatr Oncol. 2016;7(6):457–462. doi:10.1016/j.jgo.2016.05.006
   PubMed Web of Science ®Google Scholar
• Extermann M, Boler I, Reich RR, et al. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer. 2012;118(13):3377–3386. doi:10.1002/cncr.26646
   PubMed Web of Science ®Google Scholar
• Bossi P, Vecchio AE, Gurizzan C, et al. Role of geriatric assessment in tailoring treatment of locally advanced head and neck cancer: the ELDERLY study. Annals Oncol. 2021;32:S789. doi:10.1016/j.annonc.2021.08.1274
   Web of Science ®Google Scholar
• Belgioia L, De Felice F, Bacigalupo A, et al. Results of a survey on elderly head and neck cancer patients on behalf of the Italian Association of Radiotherapy and Clinical Oncology (AIRO). Acta Otorhinolaryngol Ital. 2020;40(6):405–409. doi:10.14639/0392-100X-N0618
   PubMed Web of Science ®Google Scholar
• Mell LK, Dignam JJ, Salama JK, et al. Predictors of competing mortality in advanced head and neck cancer. J Clin Oncol. 2010;28(1):15–20. doi:10.1200/JCO.2008.20.9288
   PubMed Web of Science ®Google Scholar
• Carmona R, Zakeri K, Green G, et al. Improved method to stratify elderly patients with cancer at risk for competing events. J Clin Oncol. 2016;34(11):1270–1277. doi:10.1200/JCO.2015.65.0739
   PubMed Web of Science ®Google Scholar
• Mell LK, Shen H, Nguyen-Tân PF, et al. Nomogram to predict the benefit of intensive treatment for locoregionally advanced head and neck cancer. Clin Cancer Res. 2019;25(23):7078–7088. doi:10.1158/1078-0432.CCR-19-1832
   PubMed Web of Science ®Google Scholar
• Nelson TJ, Thompson CA, Zou J, et al. Validation of NRG Oncology’s prognostic nomograms for oropharyngeal cancer in the Veterans Affairs database. Cancer. 2022;128(10):1948–1957. doi:10.1002/cncr.34141
   PubMed Web of Science ®Google Scholar
• Vitzthum LK, Feng CH, Noticewala S, et al. Comparison of comorbidity and frailty indices in patients with head and neck cancer using an online tool. JCO Clin Cancer Inform. 2018;2(2):1–9. doi:10.1200/CCI.18.00082
   Google Scholar
• Zakeri K, Rotolo F, Lacas B, et al. Predictive classifier for intensive treatment of head and neck cancer. Cancer. 2020;126(24):5263–5273. doi:10.1002/cncr.33212
   PubMed Web of Science ®Google Scholar
• Bourhis J, Overgaard J, Audry H, et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet. 2006;368(9538):843–854. doi:10.1016/S0140-6736(06)69121-6
   PubMed Web of Science ®Google Scholar
• Mell L, Vitzthum L, Wong H, et al. Comogram: an online tool to inform clinical decision making for cancer patients based on their competing risks. 2019; Available from: www.comogram.org. Accessed March 6, 2023.
   Google Scholar
• Ruhle A, Stromberger C, Haehl E, et al. Development and validation of a novel prognostic score for elderly head-and-neck cancer patients undergoing radiotherapy or chemoradiation. Radiother Oncol. 2021;154:276–282. doi:10.1016/j.radonc.2020.11.023
   PubMed Web of Science ®Google Scholar
• Zhou W, Peng C, Liu Z, et al. A novel clinical signature predicts the survival of elderly patients with oral squamous cell carcinoma. Eur Arch Otorhinolaryngol. 2022;279(1):391–398. doi:10.1007/s00405-021-06786-6
   PubMed Web of Science ®Google Scholar
• Kou J, Zhang -L-L, Yang X-L, et al. Development of a nomogram model for treatment of elderly patients with locoregionally advanced nasopharyngeal carcinoma. J Pers Med. 2021;11(11):1065. doi:10.3390/jpm11111065
   PubMed Web of Science ®Google Scholar
• Turrentine FE, Wang H, Simpson VB, et al. Surgical risk factors, morbidity, and mortality in elderly patients. J Am Coll Surg. 2006;203(6):865–877. doi:10.1016/j.jamcollsurg.2006.08.026
   PubMed Web of Science ®Google Scholar
• Spyropoulou GA, Jeng S-F, Hsieh C-H, et al. Microsurgical reconstruction for head and neck cancer in elderly patients. J Reconstr Microsurg. 2014;30(2):91–96. doi:10.1055/s-0033-1357277
   PubMed Web of Science ®Google Scholar
• Bhama PK, Patel S, Khan U, et al. Head and neck free flap reconstruction in patients older than 80 years. J Reconstr Microsurg. 2014;30(8):523–530. doi:10.1055/s-0034-1384664
   PubMed Web of Science ®Google Scholar
• L’Esperance HE, Kallogjeri D, Yousaf S, et al. Prediction of mortality and morbidity in head and neck cancer patients 80 years of age and older undergoing surgery. Laryngoscope. 2018;128(4):871–877. doi:10.1002/lary.26858
   PubMed Web of Science ®Google Scholar
• Wu Y, Zhang B, Huang Z, et al. Study of surgical treatment for elderly patients with head and neck cancer. Int J Oral Maxillofac Surg. 2018;47(7):824–829. doi:10.1016/j.ijom.2018.01.018
   PubMed Web of Science ®Google Scholar
• Goh CS, Kok Y-O, Yong CP-C, et al. Outcome predictors in elderly head and neck free flap reconstruction: a retrospective study and systematic review of the current evidence. J Plast Reconstr Aesthet Surg. 2018;71(5):719–728. doi:10.1016/j.bjps.2017.12.011
   PubMed Web of Science ®Google Scholar
• Goldstein DP, Sklar MC, Almeida JR, et al. Frailty as a predictor of outcomes in patients undergoing head and neck cancer surgery. Laryngoscope. 2020;130(5):E340–E345. doi:10.1002/lary.28222
   PubMed Web of Science ®Google Scholar
• Peters TT, van Dijk BAC, Roodenburg JLN, et al. Relation between age, comorbidity, and complications in patients undergoing major surgery for head and neck cancer. Ann Surg Oncol. 2014;21(3):963–970. doi:10.1245/s10434-013-3375-x
   PubMed Web of Science ®Google Scholar
• Peters TTA, Post SF, van Dijk BAC, et al. Free flap reconstruction for head and neck cancer can be safely performed in both young and elderly patients after careful patient selection. Eur Arch Otorhinolaryngol. 2015;272(10):2999–3005. doi:10.1007/s00405-014-3268-z
   PubMed Web of Science ®Google Scholar
• Nakayama Y, Ohkoshi A, Ishii R, et al. The geriatric-8 screening tool for predicting complications in older adults after surgery for locally advanced head and neck cancer with free flap reconstruction. Eur Arch Otorhinolaryngol. 2022;279(5):2565–2571. doi:10.1007/s00405-021-07038-3
   PubMedGoogle Scholar
• Grammatica A, Piazza C, Paderno A, et al. Free flaps in head and neck reconstruction after oncologic surgery: expected outcomes in the elderly. Otolaryngol Head Neck Surg. 2015;152(5):796–802. doi:10.1177/0194599815576905
   PubMed Web of Science ®Google Scholar
• Wester JL, Lindau RH, Wax MK. Efficacy of free flap reconstruction of the head and neck in patients 90 years and older. JAMA Otolaryngol Head Neck Surg. 2013;139(1):49–53. doi:10.1001/jamaoto.2013.1138
   PubMed Web of Science ®Google Scholar
• Beausang ES, Ang EE, Lipa JE, et al. Microvascular free tissue transfer in elderly patients: the Toronto experience. Head Neck. 2003;25(7):549–553. doi:10.1002/hed.10240
   PubMed Web of Science ®Google Scholar
• Jalisi S, Rubin SJ, Wu KY, et al. Outcomes of head and neck cancer surgery in the geriatric population based on case volume at academic centers. Laryngoscope. 2017;127(11):2539–2544. doi:10.1002/lary.26750
   PubMed Web of Science ®Google Scholar
• Rubin SJ, Wu KY, Kirke DN, et al. Head and neck cancer complications in the geriatric population based on hospital case volume. Ear Nose Throat J. 2021;100(2):NP62–NP68. doi:10.1177/0145561319856006
   PubMed Web of Science ®Google Scholar
• Jackson RS, Chen S, Last A, et al. Multi-institutional analysis of outcomes following transoral surgery for HPV-positive oropharyngeal squamous cell carcinoma in elderly patients. Head Neck. 2019;41(11):3933–3939. doi:10.1002/hed.25946
   PubMed Web of Science ®Google Scholar
• Rodrigo JP, García‐Velasco F, Ambrosch P, et al. Transoral laser microsurgery for glottic cancer in the elderly: efficacy and safety. Head Neck. 2019;41(6):1816–1823. doi:10.1002/hed.25616
   PubMed Web of Science ®Google Scholar
• Lee C, Forner D, Noel CW, et al. Functional and oncologic outcomes of octogenarians undergoing transoral laser microsurgery for laryngeal cancer. OTO Open. 2021;5(3):2473974X211046957. doi:10.1177/2473974X211046957
   PubMedGoogle Scholar
• Hendriksma M, Heijnen BJ, Sjogren EV. Oncologic and functional outcomes of patients treated with transoral CO2 laser microsurgery or radiotherapy for T2 glottic carcinoma: a systematic review of the literature. Curr Opin Otolaryngol Head Neck Surg. 2018;26(2):84–93. doi:10.1097/MOO.0000000000000438
   PubMed Web of Science ®Google Scholar
• Spielmann PM, Majumdar S, Morton RP. Quality of life and functional outcomes in the management of early glottic carcinoma: a systematic review of studies comparing radiotherapy and transoral laser microsurgery. Clin Otolaryngol. 2010;35(5):373–382. doi:10.1111/j.1749-4486.2010.02191.x
   PubMed Web of Science ®Google Scholar
• Gokmen MF, Buyukatalay ZC, Beton S, et al. Functional and oncological outcomes of open partial laryngectomy vs. transoral laser surgery in supraglottic larynx cancer. Turk Arch Otorhinolaryngol. 2020;58(4):227–233. doi:10.5152/tao.2020.5573
   PubMedGoogle Scholar
• Withers HR, Taylor JM, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol. 1988;27(2):131–146. doi:10.3109/02841868809090333
   PubMed Web of Science ®Google Scholar
• Shuryak I, Hall EJ, Brenner DJ. Optimized hypofractionation can markedly improve tumor control and decrease late effects for head and neck cancer. Int J Radiat Oncol Biol Phys. 2019;104(2):272–278. doi:10.1016/j.ijrobp.2019.02.025
   PubMed Web of Science ®Google Scholar
• Toya R. Hypofractionated palliative volumetric modulated arc radiotherapy with the Radiation Oncology Study Group 8502 “QUAD shot” regimen for incurable head and neck cancer. Radiat Oncol. 2020;15(1):123. doi:10.1186/s13014-020-01548-w
   PubMed Web of Science ®Google Scholar
• Kancherla KN, Oksuz DC, Prestwich RJ, et al. The role of split-course hypofractionated palliative radiotherapy in head and neck cancer. Clin Oncol. 2011;23(2):141–148. doi:10.1016/j.clon.2010.09.006
   Web of Science ®Google Scholar
• Pearson RA, Bannister-Young RH, Ivison D, et al. Split-course hypofractionated palliative radiotherapy for patients with head and neck squamous cell carcinoma - a worthwhile treatment schedule in the UK? Clin Oncol. 2010;22(10):890–891. doi:10.1016/j.clon.2010.06.003
   Web of Science ®Google Scholar
• Al-mamgani A, Tans L, Van Rooij PHE, et al. Hypofractionated radiotherapy denoted as the “Christie scheme”: an effective means of palliating patients with head and neck cancers not suitable for curative treatment. Acta Oncol. 2009;48(4):562–570. doi:10.1080/02841860902740899
   PubMed Web of Science ®Google Scholar
• Corry J, Peters LJ, Costa ID, et al. The ‘QUAD SHOT’--a Phase II study of palliative radiotherapy for incurable head and neck cancer. Radiother Oncol. 2005;77(2):137–142. doi:10.1016/j.radonc.2005.10.008
   PubMed Web of Science ®Google Scholar
• Lok BH, Jiang G, Gutiontov S, et al. Palliative head and neck radiotherapy with the RTOG 8502 regimen for incurable primary or metastatic cancers. Oral Oncol. 2015;51(10):957–962. doi:10.1016/j.oraloncology.2015.07.011
   PubMed Web of Science ®Google Scholar
• Ferro M, Macchia G, Re A, et al. Advanced head and neck cancer in older adults: results of a short course accelerated radiotherapy trial. J Geriatr Oncol. 2021;12(3):441–445. doi:10.1016/j.jgo.2020.10.006
   PubMed Web of Science ®Google Scholar
• Thomson DJ, Palma D, Guckenberger M, et al. Practice recommendations for risk-adapted head and neck cancer radiotherapy during the COVID-19 pandemic: an ASTRO-ESTRO consensus statement. Radiother Oncol. 2020;151:314–321. doi:10.1016/j.radonc.2020.04.019
   PubMed Web of Science ®Google Scholar
• Bledsoe TJ, Noble AR, Reddy CA, et al. Split-Course Accelerated Hypofractionated Radiotherapy (SCAHRT): a safe and effective option for head and neck cancer in the elderly or infirm. Anticancer Res. 2016;36(3):933–939.
   PubMed Web of Science ®Google Scholar
• Hall EJ. Radiobiology for the Radiologist. Hagerstown, Md: Medical Dept., Harper & Row; 1973.
   Google Scholar
• Ortholan C, Auperin A, Mertens C, et al. Radiothérapie hypofractionnée des cancers ORL chez le sujet âgé [Hypofractionad radiotherapy for elderly with head and neck cancer]. Cancer Radiother. 2018;22(6–7):640–643. French. doi:10.1016/j.canrad.2018.06.008
   PubMedGoogle Scholar
• Dickstein DR, Egerman MA, Bui AH, et al. A new face of the HPV epidemic: oropharyngeal cancer in the elderly. Oral Oncol. 2020;109:104687. doi:10.1016/j.oraloncology.2020.104687
   PubMed Web of Science ®Google Scholar
• Dave E, Lehrer EJ, Hsieh K, et al. Human papilloma virus-positive oropharyngeal squamous cell carcinoma in the elderly. Anticancer Res. 2017;37(4):1847–1851.
   PubMed Web of Science ®Google Scholar
• Dickstein DR. Hypofractionated radiotherapy for elderly patients with head and neck squamous cell carcinoma - interim results from a propective phase II trial. in American Radium Society. Scottsdale, Arizona; 2022.
   Google Scholar
• Dickstein DR, Lehrer EJ, Hsieh K, et al. Management of older adults with locally advanced head and neck cancer. Cancers. 2022;14(11):2809. doi:10.3390/cancers14112809
   PubMed Web of Science ®Google Scholar
• Michal SA, Adelstein DJ, Rybicki LA, et al. Multi-agent concurrent chemoradiotherapy for locally advanced head and neck squamous cell cancer in the elderly. Head Neck. 2012;34(8):1147–1152. doi:10.1002/hed.21891
   PubMed Web of Science ®Google Scholar
• Machtay M, Moughan J, Trotti A, et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol. 2008;26(21):3582–3589. doi:10.1200/JCO.2007.14.8841
   PubMed Web of Science ®Google Scholar
• Mayer A, Wenzel W, Wollschläger D, et al. Adjuvant chemoradiotherapy in elderly patients with head and neck cancer: a monoinstitutional, two-to-one pair-matching analysis. Strahlenther Onkol. 2022;198(2):159–170. doi:10.1007/s00066-021-01890-2
   PubMed Web of Science ®Google Scholar
• Sachdev S, Refaat T, Bacchus ID, et al. Age most significant predictor of requiring enteral feeding in head-and-neck cancer patients. Radiat Oncol. 2015;10(1):93. doi:10.1186/s13014-015-0408-6
   PubMedGoogle Scholar
• De Felice F, Vetrone L, Bulzonetti N, et al. Hypofractionated radiotherapy combined with cetuximab in vulnerable elderly patients with locally advanced head and neck squamous cell carcinoma. Med Oncol. 2019;36(8):68. doi:10.1007/s12032-019-1292-y
   PubMed Web of Science ®Google Scholar
• Sarris EG, Harrington KJ, Saif MW, et al. Multimodal treatment strategies for elderly patients with head and neck cancer. Cancer Treat Rev. 2014;40(3):465–475. doi:10.1016/j.ctrv.2013.10.007
   PubMed Web of Science ®Google Scholar
• Park JW, Roh J-L, Lee S-W, et al. Effect of polypharmacy and potentially inappropriate medications on treatment and posttreatment courses in elderly patients with head and neck cancer. J Cancer Res Clin Oncol. 2016;142(5):1031–1040. doi:10.1007/s00432-015-2108-x
   PubMed Web of Science ®Google Scholar
• Pignon JP, Bourhis J, Domenge C, et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet. 2000;355(9208):949–955. doi:10.1016/S0140-6736(00)90011-4
   PubMed Web of Science ®Google Scholar
• Nehlsen AD, Lehrer EJ, Dickstein DR, et al. Functional larynx preservation in patients with locally advanced squamous cell carcinoma of the larynx and hypopharynx treated with induction chemotherapy vs. concurrent chemoradiation alone. Cureus. 2021;13(7):e16310. doi:10.7759/cureus.16310
   PubMed Web of Science ®Google Scholar
• Blanchard P, Baujat B, Holostenco V, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. Radiother Oncol. 2011;100(1):33–40. doi:10.1016/j.radonc.2011.05.036
   PubMed Web of Science ®Google Scholar
• Lacas B, Carmel A, Landais C, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. Radiother Oncol. 2021;156:281–293. doi:10.1016/j.radonc.2021.01.013
   PubMed Web of Science ®Google Scholar
• Amini A, Jones BL, McDermott JD, et al. Survival outcomes with concurrent chemoradiation for elderly patients with locally advanced head and neck cancer according to the National Cancer Data Base. Cancer. 2016;122(10):1533–1543. doi:10.1002/cncr.29956
   PubMed Web of Science ®Google Scholar
• Ward MC, Reddy CA, Adelstein DJ, et al. Use of systemic therapy with definitive radiotherapy for elderly patients with head and neck cancer: a National Cancer Data Base analysis. Cancer. 2016;122(22):3472–3483. doi:10.1002/cncr.30214
   PubMed Web of Science ®Google Scholar
• Zandberg DP, Cullen K, Bentzen SM, et al. Definitive radiation with concurrent cetuximab vs. radiation with or without concurrent cytotoxic chemotherapy in older patients with squamous cell carcinoma of the head and neck: analysis of the SEER-medicare linked database. Oral Oncol. 2018;86:132–140. doi:10.1016/j.oraloncology.2018.09.023
   PubMed Web of Science ®Google Scholar
• VanderWalde NA, Meyer AM, Deal AM, et al. Effectiveness of chemoradiation for head and neck cancer in an older patient population. Int J Radiat Oncol Biol Phys. 2014;89(1):30–37. doi:10.1016/j.ijrobp.2014.01.053
   PubMed Web of Science ®Google Scholar
• McDermott JD, Amini A, Molina E, et al. Treatment outcomes and cost comparisons for older adults with T4 laryngeal squamous cell cancer. Head Neck. 2023;45(3):664–674. doi:10.1002/hed.27284
   PubMed Web of Science ®Google Scholar
• Hurria A, Levit LA, Dale W, et al. Improving the evidence base for treating older adults with cancer: American Society of clinical oncology statement. J Clin Oncol. 2015;33(32):3826–3833. doi:10.1200/JCO.2015.63.0319
   PubMed Web of Science ®Google Scholar
• Kanesvaran R, Cordoba R, Maggiore R. Immunotherapy in older adults with advanced cancers: implications for clinical decision-making and future research. Am Soc Clin Oncol Educ Book. 2018;38(38):400–414. doi:10.1200/EDBK_201435
   PubMedGoogle Scholar
• Muller L, Di Benedetto S, Pawelec G. The immune system and its dysregulation with aging. Subcell Biochem. 2019;91:21–43.
   PubMedGoogle Scholar
• Wagner A, Garner-Spitzer E, Jasinska J, et al. Age-related differences in humoral and cellular immune responses after primary immunisation: indications for stratified vaccination schedules. Sci Rep. 2018;8(1):9825. doi:10.1038/s41598-018-28111-8
   PubMedGoogle Scholar
• Nishijima TF, Muss HB, Shachar SS, et al. Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: a systematic review and meta-analysis. Cancer Treat Rev. 2016;45:30–37. doi:10.1016/j.ctrv.2016.02.006
   PubMed Web of Science ®Google Scholar
• Elias R, Giobbie-Hurder A, McCleary NJ, et al. Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis. J Immunother Cancer. 2018;6(1):26. doi:10.1186/s40425-018-0336-8
   PubMed Web of Science ®Google Scholar
• Ridolfi L, De Rosa F, Petracci E, et al. Anti-PD1 antibodies in patients aged >/= 75 years with metastatic melanoma: a retrospective multicentre study. J Geriatr Oncol. 2020;11(3):515–522. doi:10.1016/j.jgo.2019.12.012
   PubMed Web of Science ®Google Scholar
• Van holstein Y, Kapiteijn E, Bastiaannet E, et al. Efficacy and adverse events of immunotherapy with checkpoint inhibitors in older patients with cancer. Drugs Aging. 2019;36(10):927–938. doi:10.1007/s40266-019-00697-2
   PubMed Web of Science ®Google Scholar
• Sacco AG, Chen R, Worden FP, et al. Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, Phase 2 trial. Lancet Oncol. 2021;22(6):883–892. doi:10.1016/S1470-2045(21)00136-4
   PubMed Web of Science ®Google Scholar
• Moretti JA. Sensori-neural hearing loss following radiotherapy to the nasopharynx. Laryngoscope. 1976;86(4):598–602. doi:10.1288/00005537-197604000-00018
   PubMed Web of Science ®Google Scholar
• Brock P, Bellman S. Ototoxicity of cisplatinum. Br J Cancer. 1991;63(1):159–160. doi:10.1038/bjc.1991.35
   PubMed Web of Science ®Google Scholar
• Skinner R, Pearson A, Amineddine HA, et al. Ototoxicity of cisplatinum in children and adolescents. Br J Cancer. 1990;61(6):927–931. doi:10.1038/bjc.1990.208
   PubMed Web of Science ®Google Scholar
• Pan CC, Eisbruch A, Lee JS, et al. Prospective study of inner ear radiation dose and hearing loss in head-and-neck cancer patients. Int J Radiat Oncol Biol Phys. 2005;61(5):1393–1402. doi:10.1016/j.ijrobp.2004.08.019
   PubMed Web of Science ®Google Scholar
• Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol. 2004;22(22):4626–4631. doi:10.1200/JCO.2004.02.175
   PubMed Web of Science ®Google Scholar
• Camet ML, Spence A, Hayashi SS, et al. Cisplatin ototoxicity: examination of the impact of dosing, infusion times, and schedules in pediatric cancer patients. Front Oncol. 2021;11:673080. doi:10.3389/fonc.2021.673080
   PubMed Web of Science ®Google Scholar
• Hitchcock YJ, Tward JD, Szabo A, et al. Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head-and-neck cancer patients. Int J Radiat Oncol Biol Phys. 2009;73(3):779–788. doi:10.1016/j.ijrobp.2008.05.040
   PubMed Web of Science ®Google Scholar
• Schuette A, Lander DP, Kallogjeri D, et al. Predicting hearing loss after radiotherapy and cisplatin chemotherapy in patients with head and neck cancer. JAMA Otolaryngol Head Neck Surg. 2020;146(2):106–112. doi:10.1001/jamaoto.2019.3550
   PubMed Web of Science ®Google Scholar
• Deutsch BC, Collopy C, Kallogjeri D, et al. Validation of hearing loss prediction tool for cisplatin chemotherapy and radiation in head and neck cancer treatment. JAMA Otolaryngol Head Neck Surg. 2021;147(2):182–189. doi:10.1001/jamaoto.2020.4620
   PubMed Web of Science ®Google Scholar